Stylus Medicine
MA - CambridgeBiotechnology
Focus: Stylus Medicine is a Cambridge-based enzymatic gene therapy biotech company focused on developing novel therapeutic approaches in the gene therapy space. With 51-200 employees and public status since 2011, they operate as a mid-cap specialized player in a high-growth therapeutic area.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
5+5 this month
Growing — net +5 jobs in 30d
5 jobs added vs 0 removed. Steady team buildout.
Should You Work at Stylus Medicine?
AI assessmentStylus Medicine represents a specialized, early-stage public biotech bet suited for researchers and scientists committed to gene therapy innovation, but with limited immediate career mobility and significant clinical/commercial timeline risk.
Why Work Here
- Focused expertise in enzymatic gene therapy—a cutting-edge modality with significant clinical and commercial upside potential
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Stylus Medicine
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.